STAT2 min read
STAT+: Pharmalittle: We’re Reading About Abortion Pill Access, Employer Coverage Of GLP-1 Drugs And More
Updates from the Pharmalittle newsletter campus: —FDA advised drugmakers to update Covid vaccines to target the KP.2 strain —Leadership from Done startup were arrested and charged with fraud —U.S. authorities…
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Pfizer Drug For Duchenne, Bird Flu Vaccines For Cows, And More
Pfizer reported that its gene therapy for Duchenne muscular dystrophy failed to slow disease progression in a Phase 3 trial.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Sanders Dogging Novo Nordisk, Teva Patents, And More
U.S. Senate health committee chair Bernie Sanders called a vote to subpoena the chief of Novo Nordisk’s U.S. division over pricing of Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Alzheimer’s Drug, An EU Contract For Bird Flu Vaccine, And More
Advisers to the FDA voted unanimously to recommend the approval of a drug for early Alzheimer’s disease made by Eli Lilly.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Moderna Covid-flu Vaccine, A Paused Pfizer Study, And More
Moderna announced its combination Covid and flu vaccine generated stronger immune responses in older adults in a Phase 3 trial than individual vaccines.
STAT1 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Alzheimer’s Drug, The GSK-Elsie Deal, And More
In today's Pharmalittle roundup, we're reading about Eli Lilly's Alzheimer's drug, the GSK-Elsie deal, and more.
STAT1 min read
STAT+: Stephen Quake On The Chan Zuckerberg Quest To Cure, Prevent, Or Manage All Diseases By 2100
Stephen Quake, head of science for the Chan Zuckerberg Initiative, is trying to get the scientific community to work together toward a hugely ambitious goal of vanquishing disease by 2100.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About The Aftermath Of FDA Vote On MDMA, Rising Pharma Layoffs, And More
A day after an FDA advisory panel expressed deep concerns about using MDMA for PTSD, companies developing other psychedelics said they remain optimistic.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MDMA ‘No’ Votes, A Gilead Settlement, And More
In a surprisingly strong rejection, a FDA scientific advisory panel overwhelmingly voted against the use of MDMA for treating PTSD.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An FDA Meeting On MDMA, A New Obesity Pill, And More
Structure Therapeutics disclosed that its oral obesity drug helped reduce weight by 6.2% on average in a mid-stage study, exceeding Wall Street expectations.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Zantac Lawsuits, Worries Over MDMA For PTSD, And More
AstraZeneca’s longest-serving chief executive, Pascal Soriot, has no plans to step down as the company aims to almost double revenue by the decade's end.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Docs Paid For Endorsements, Novartis Suing Maryland, And Lots More
In today's Pharmalittle roundup, we're reading about docs paid for endorsements, Novartis suing Maryland, and lots more.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Deal For A Moderna Bird Flu Shot, NIH Trial Shortcomings, And More
The U.S. government is nearing an agreement to bankroll a late-stage trial of Moderna’s mRNA pandemic bird flu vaccine, hoping to bolster its pandemic stockpile.
STAT1 min read
STAT+: Akili, Maker Of A Video Game To Treat ADHD, To Be Acquired For $34 Million
Akili Interactive, maker of a video game designed to treat ADHD, said it will go private in a merger with Virtual Therapeutics.
STAT1 min read
Opinion: Saving Rural Psychiatry Services Will Require Higher Medicaid Payments
Unless Medicaid raises its payments to rural psychiatrists, mental health clinics across the heartland will disappear, and with it the mental health care for the patients they serve.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Merck Deal, Weight Loss Drugs, And Lots More
Merck has struck a $1.3 billion deal to buy Eyebiotech, a move that would push the big drugmaker into the large and growing market for eye care.
STAT1 min read
STAT+: Gene Therapies For Deafness Dredge Up An Old Question: Do Deaf People Want A ‘Cure’?
As scientists celebrate gene therapy's ability to enable hearing, deaf people are feeling a familiar dread: Are we endangered?
STAT2 min read
STAT+: Pharmalittle: We’re Reading About The Cencora Data Breach, A Failed Pandemic Treaty, And More
Almost a dozen pharmaceutical companies have lost sensitive customer data due to a supply chain cyberattack that trickled down from Cencora.
STAT1 min read
Opinion: STAT+: Unmasking The ‘Centricity’ Illusion In Clinical Trials
The glacial pace of change in mechanistic but essential areas of clinical trials undermines the biopharma industry's claims of progress and compassion.
STAT1 min read
STAT+: After MDMA Therapy, She Considered Suicide. The Trial Data Tell A Different Story
Critics argue that a pattern of inconsistencies in the MDMA clinical trial data and other shortcomings compromise the integrity of the studies.
STAT1 min read
STAT+: Pharmalittle: We’re Watching More Positive Data For Ozempic, A Lilly Factory Expansion, And More
Ozempic cut the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20% in a trial of patients with type 2 diabetes and chronic kidney disease.
STAT1 min read
STAT+: Pharmalittle: We’re Watching A Cytokinetics Deal With Royalty Pharma, Cue Health Shutting Down, And More
Cytokinetics did a deal with Royalty Pharma, the biotech firm that has become a huge success by buying up small shares of other companies’ drugs.
STAT1 min read
STAT+: Pharmalittle: We’re Watching A Ban Of Compounded Versions Of GLP-1s, A Biogen Acquisition, And More
Good morning from San Diego. This is Jonathan Wosen, West Coast biotech and life sciences reporter, filling in for Ed Silverman while he’s away from the Pharmalittle campus. I’m not a coffee drinker, but who needs caffeine when you’ve got the raw adr
STAT1 min read
STAT+: Pharmalittle: We’re Watching BIO Layoffs, AstraZeneca Plans To Double Revenue, And More
The Biotechnology Innovation Organization on Monday announced 30 layoffs that are part of a restructuring.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Sanders’ Pharma Pressure Campaign, AstraZeneca’s New ADC Factory, And More
Sen. Bernie Sanders is testing the limits of the powers of a Senate chairman with little hope of advancing his drug-pricing agenda legislatively.
STAT1 min read
Opinion: HHS’s Proposed Rule Pays Lip Service To Addressing The Climate Crisis, The Greatest Threat To Human Health
HHS's proposal for addressing the climate crisis serves as an example of what historian and philosopher Hannah Arendt defined as the "banality of evil."
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Drug For Lung Cancer, A Novo Plant Fire, And More
The FDA approved an innovative treatment from Amgen for patients with small cell lung cancer who have exhausted all other options.
STAT1 min read
STAT+: Wearable Devices Generate Powerful Data But It’s Not Useful To Doctors, Yet
Data from wearables can be powerful but they're not useful to doctors yet, experts said at the #STATBreakthrough Summit in San Francisco.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Roche Obesity Drug, An Experimental Lilly Insulin, And More
Roche disclosed that its recently acquired experimental obesity medication helped people lose a significant amount of weight in a Phase 1 trial.
STAT1 min read
STAT+: Microsoft’s Peter Lee Says ChatGPT Shouldn’t Be Used For Initial Diagnosis
Speaking at #STATBreakthrough Summit, Microsoft’s Peter Lee talked about how ChatGPT and generative AI still have tricky blindspots.
…Or Discover Something New